Application of lasiokaurin in preparation of medicine for resisting triple negative breast cancer or STARD7 inhibitor

The invention discloses application of lasiokaurin in preparation of a medicine for resisting triple negative breast cancer or an STARD7 inhibitor, and relates to the technical field of triple negative breast cancer resistance. A new strategy is provided for treatment of triple negative breast cancer (TNBC), and ferroptosis of triple negative breast cancer cells can be induced by targeting STARD7 and inhibiting the activity or effect of STARD7, and meanwhile, apoptosis and necrosis are accompanied, so that the disease progress of the triple negative breast cancer is influenced. In addition, the invention also provides an application of the lasiokaurin in preparation of an inducer for inducing ferroptosis of triple negative breast cancer cells and an application of the lasiokaurin in preparation of a specific inhibitor of StAR-related lipid transfer domain 7. 本发明公开了毛栲利素在制备抗三阴性乳腺癌的药物或STARD7抑制剂中的应用，涉及抗三阴性乳腺癌技术领域。本发明为三阴性乳腺癌(TNBC)的治疗提供了新的策略，通过靶向STARD7，抑制STARD7的活性或作用能够诱使三阴性乳腺癌细胞发生铁死亡，同时伴随着凋亡和坏死，从而对三阴性乳腺癌的疾病进展产生影响。此